Estrella Immunopharma

Historical price data

Estrella Immunopharma's mission is to extend the curative power of T-cell therapies to a broader range of cancers and autoimmune diseases by addressing the critical limitations of current CAR-T products. The company has achieved an 83% overall response rate in a proof-of-concept study for B-cell lymphoma with its lead ARTEMIS candidate, EB103, and reported no severe CRS. Its strategy involves first advancing its CD19-targeted programs in hematologic malignancies, then leveraging a unique oncolytic virus-based 'mark-and-kill' platform to tackle the vast solid tumor market, while also exploring applications in autoimmune conditions like lupus.

Proprietary CD19-Redirected ARTEMIS T Cell platform, engineered to integrate with native CD3 signaling to reduce cytokine-related toxicities, combined with a 'mark-and-kill' approach using oncolytic viruses to target solid tumors.

Faces direct competition from six approved CAR-T products in hematology and numerous biotechs developing next-gen constructs. In solid tumors, it competes in an open field with unproven platforms. Estrella's differentiation hinges on proving superior safety and its unique combinatorial viral approach.